← Back to Screener
PDS Biotechnology Corporation Common Stock (PDSB)
Price$1.29
Favorite Metrics
Price vs S&P 500 (26W)28.08%
Price vs S&P 500 (4W)117.98%
Market Capitalization$72.00M
All Metrics
Book Value / Share (Quarterly)$0.17
P/TBV (Annual)4.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.51
Price vs S&P 500 (YTD)63.65%
EPS (TTM)$-0.75
10-Day Avg Trading Volume1.58M
EPS Excl Extra (TTM)$-0.75
EPS (Annual)$-0.74
ROI (Annual)-131.78%
Cash / Share (Quarterly)$0.49
ROA (Last FY)-113.12%
EBITD / Share (TTM)$-0.68
ROE (5Y Avg)-170.94%
Cash Flow / Share (Annual)$-0.51
P/B Ratio7.78x
P/B Ratio (Quarterly)4.55x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-10.83x
ROA (TTM)-90.36%
EPS Incl Extra (Annual)$-0.74
Current Ratio (Annual)2.98x
Quick Ratio (Quarterly)2.82x
3-Month Avg Trading Volume0.72M
52-Week Price Return19.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.72
52-Week High$1.92
EPS Excl Extra (Annual)$-0.74
Tangible BV CAGR (5Y)-6.74%
26-Week Price Return34.97%
Quick Ratio (Annual)2.82x
13-Week Price Return36.55%
Total Debt / Equity (Annual)1.83x
Current Ratio (Quarterly)2.98x
Enterprise Value$62.216
Book Value / Share Growth (5Y)-32.63%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.49
3-Month Return Std Dev111.23%
Net Income / Employee (TTM)$-1
ROE (Last FY)-372.85%
Net Interest Coverage (Annual)-7.65x
EPS Basic Excl Extra (Annual)$-0.74
Total Debt / Equity (Quarterly)1.83x
EPS Incl Extra (TTM)$-0.75
ROI (TTM)-106.62%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.46
Price vs S&P 500 (52W)-15.19%
Year-to-Date Return67.58%
5-Day Price Return21.70%
EPS Normalized (Annual)$-0.74
ROA (5Y Avg)-69.32%
Month-to-Date Return113.22%
Cash Flow / Share (TTM)$-1.69
EBITD / Share (Annual)$-0.70
LT Debt / Equity (Annual)1.27x
ROI (5Y Avg)-79.47%
LT Debt / Equity (Quarterly)1.27x
EPS Basic Excl Extra (TTM)$-0.75
P/TBV (Quarterly)1.24x
P/B Ratio (Annual)4.55x
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)34.17%
Beta1.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-241.96%
52-Week Low$0.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PDSBPDS Biotechnology Corporation Common Stock | — | — | — | — | $1.29 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
PDS Biotechnology is a clinical-stage immunotherapy company developing cancer treatments across multiple indications including head and neck, breast, prostate, cervical, and anal cancers. The company's proprietary Versamune platform harnesses the immune system to specifically target cancer cells. Its pipeline is built on this differentiated technology platform.